# A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct05421663/  
OnCo record `nct05421663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JNJ-90014496 in non-hodgkin lymphoma, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05421663 by Janssen Research & Development, LLC, with 166 participants enrolled, started 2022-08-12 and due to reach its primary completion in 2041-07-30. Interventions recorded: JNJ-90014496. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05421663
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 166

## Sources

- ClinicalTrials.gov NCT05421663: https://clinicaltrials.gov/study/NCT05421663

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [JNJ-90014496](https://onco.cc/drugs/jnj-90014496/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05421663.json